Welcome to our dedicated page for Metagenomi Therapeutics SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi Therapeutics director Reid Laurence received a grant of stock options covering 17,400 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They vest on the earlier of one year from the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.
Metagenomi Therapeutics director Dere Willard H received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. These options vest in full on the earlier of one year after the grant date or the company’s 2027 annual stockholder meeting, provided he continues serving the company through that vesting date.
Metagenomi Therapeutics director Eric Bjerkholt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and give the right to buy 21,000 shares once vested.
The options vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date. Following this grant, his reported holdings of this option award total 21,000 derivative securities.
Metagenomi Therapeutics, Inc. director Juergen Eckhardt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company's 2027 annual meeting of stockholders, subject to his continued service with the company. After this award, he holds 21,000 stock options directly.
Metagenomi Therapeutics, Inc. reported that Chief Financial Officer Pamela Wapnick had 2,884 shares of common stock sold at $1.299 per share. According to the footnote, these shares were automatically sold to cover tax withholding on vested restricted stock units and were not a discretionary trade. Following the transaction, she directly holds 208,491 shares.
Metagenomi Therapeutics director and officer Jian Irish reported an automatic share sale tied to tax withholding. On June 5, 2026, 3,737 shares of Metagenomi Therapeutics, Inc. common stock were sold at $1.299 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025. The filing states this was not a voluntary trade. After the sale, she holds 377,533 shares of common stock directly, and additional shares are held indirectly through family trusts for which she reports but disclaims full beneficial ownership. A footnote also notes that her holdings include 1,500 shares acquired under the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics, Inc. officer Matthew Wein reported an automatic sale of 558 shares of common stock at $1.299 per share on June 5, 2026. The shares were sold solely to satisfy tax withholding obligations triggered by the vesting of restricted stock units and were not a voluntary trade.
After this transaction, Wein directly held 126,491 common shares, which includes 1,500 shares acquired through the company’s employee stock purchase plan on May 29, 2026.
Metagenomi Therapeutics, Inc. reported that Brian C. Thomas, Ph.D. resigned from its board of directors effective June 9, 2026, and the company stated his resignation was not due to any disagreement over operations, policies or practices. On the same date, Metagenomi held its 2026 annual stockholder meeting by virtual webcast. A quorum was established with 19,116,207 shares present or represented by proxy out of 37,647,057 shares outstanding and entitled to vote as of the April 13, 2026 record date. Stockholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors to serve until the 2029 annual meeting, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Metagenomi Therapeutics reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and available-for-sale marketable securities were $140.2 million as of March 31, 2026, and management anticipates this cash runway will support operations through the fourth quarter of 2027.
For the quarter, collaboration revenue was $1.25 million compared with $4.13 million a year earlier. Research and development expenses were $19.3 million versus $25.1 million, and general and administrative expenses were $6.5 million versus $6.8 million. Net loss was $23.1 million, or $0.61 per share, compared with a net loss of $25.0 million, or $0.68 per share, in the prior-year period.
The company highlighted continued progress for MGX-001, its lead hemophilia A program, which it expects to submit for regulatory review, including an IND, in the fourth quarter of 2026, with first-in-human studies planned for 2027. Metagenomi also referenced a publication in Nature Structural & Molecular Biology showcasing its compact CRISPR nuclease MG119-28 and reiterated its strategy to apply its in vivo genome editing platform to hemophilia A and additional genetic and cardiometabolic indications.